In conclusion, our data support the use of TCL1A in the panel of diagnostic markers used in the differential diagnosis of splenic low-grade B-cell lymphoma; a possible biological and/or prognostic significance of this marker and the possible existence of a novel group of splenic lymphomas with an aberrant phenotype, however, need evaluation of a larger series. Here, TCL1A is linked to B-cell non-Hodgkin lymphoma.